Monographie - Etoposide phosphate - Stabilis 4.0

Last update :
08/05/2024

Anticancer drug

Etoposide phosphate

Injection

Stability in solutions

Stability of mixtures

Factors which affect stability

Compatibility

Route of administration

References

Pdf

Chemical structure

Tradename

Tradename

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Etopofos	Argentina, Austria, Denmark, Finland, Norway, Sweden
Etopophos	Belgium, Bulgaria, France, Germany, Great Britain, Israel, Luxembourg, Netherlands, New Zealand, Poland, Republic of South Africa, Switzerland, United States of America
Nexvep	Brazil
Toposar	United States of America

References

Injection

References : Etoposide phosphate

	Type	Publication
1410	Journal	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1411	Journal	Zhang Y, Trissel LA. Physical and chemical stability of etoposide phosphate solutions. J Am Pharm Assoc 1999 ; 39: 146-150.
1423	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1606	Journal	Yuan P, Grimes GJ, Shankman SE, Daniels CE, Goldspiel BR, Potti GK. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection. Am J Health-Syst Pharm 2001 ; 58: 594-598.
1625	Journal	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Journal	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1925	Journal	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1982	Journal	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247	Journal	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Journal	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3644	Manufacturer	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3655	Manufacturer	Etoposide phosphate (Etopophos®) - Résumé des caractéristiques du produit Bristol Myers Squibb 2016
3838	Manufacturer	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
4102	Journal	Svirskis D, Behera S, Naidoo N, Beachman J, Raina T, Zhou Y, Berkahn L, Costello I, Gu Y. Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastromeric pump supporting transition of the EPOCH regimen to oupatient care. J Oncol Pharm Practice 2018 ;25,4:831-840.

Mentions Légales